Human Carotid Artery Smooth Muscle Cells Rarely Express αvβ3 Integrin at Sites of Recent Plaque Rupture

Yuji Ikari; Karen O. Yee; Thomas S. Hatsukami; Stephen M. Schwartz

doi:10.1055/s-0037-1614017

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2000; 84(02): 338-344
DOI: 10.1055/s-0037-1614017

Review Article

Schattauer GmbH

Human Carotid Artery Smooth Muscle Cells Rarely Express αvβ3 Integrin at Sites of Recent Plaque Rupture

Yuji Ikari

³From the Department of Pathology, University of Washington, USA

,

Karen O. Yee

¹Department of Molecular and Cellular Biology, University of Washington, USA

,

Thomas S. Hatsukami

²Department of Vascular Surgery, University of Washington, USA

,

Stephen M. Schwartz

³From the Department of Pathology, University of Washington, USA

› Institutsangaben

Abstract

Summary

Fibrin(ogen) is the major matrix ligand for β3 integrins. If αvβ3 is the major receptor for fibrin(ogen) on intimal smooth muscle cells, we might expect to see this integrin associated with fibrin(ogen). Eightyfour specimens obtained from endarterectomies of 14 patients were studied. Fibrin was frequently observed in carotid intima even at the non-atherosclerotic areas. As for β1 and β3 integrins, β1 was predominant in intima. The αvβ3 integrin expression was less frequent than α5β1, another receptor for fibrin(ogen), in diffuse intimal thickening, fibrous cap and advanced plaques. Furthermore, αvβ3 was generally negative on smooth muscle cells in recent plaque ruptures. In conclusion, we suggest more attention should be paid on abundant fibrin matrix in intima. Histologically, the α5β1 integrin rather than the αvβ3 is the major receptor for fibrin in intimal smooth muscle cells.

Keywords

Fibrin - fibrinogen - tissue factor - immunohistochemistry - carotid endarterectomy

Volltext

Referenzen

References
1 Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months The EPIC Investigators. Lancet 1994; 343: 881-6.
2 Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention EPIC Investigators. Circulation 1995; 91: 2882-90.
3 Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 1997; 30: 149-56.
4 Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial) Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75: 559-62.
5 Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in highrisk coronary angioplasty. Circulation 1994; 90: 1757-64.
6 Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996; 78: 35-40.
7 Topol EJ. Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. Am Heart J 1995; 130: 666-72.
8 Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. Jama 1997; 278: 479-84.
9 Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 1995; 74: 302-8.
10 Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res 1995; 77: 1129-35.
11 Felding-Habermann B, Ruggeri ZM, Cheresh DA. Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments. J Biol Chem 1992; 267: 5070-7.
12 Katagiri Y, Hiroyama T, Akamatsu N, Suzuki H, Yamazaki H, Tanoue K. Involvement of alpha v beta 3 integrin in mediating fibrin gel retraction. J Biol Chem 1995; 270: 1785-90.
13 Yee KO, Rooney MM, Giachelli CM, Lord ST, Schwartz SM. Role of b1 and b3 integrins in human smooth muscle cell adhesion to and contraction of fibrin clots in vitro. Circ Res 1998; 83: 241-51.
14 Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994; 19: 125-34.
15 Matsuno H, Stassen JM, Moons L, Vermylen J, Hoylaerts MF. Neointima formation in injured hamster carotid artery is effectively prevented by the combination G4120 and quinapril. Thromb Haemost 1996; 76: 263-9.
16 Bosmans JM, Kockx MM, Vrints CJ, Bult H, De-Meyer GR, Herman AG. Fibrin(ogen) and von Willebrand factor deposition are associated with intimal thickening after balloon angioplasty of the rabbit carotid artery. Arterioscler Thromb Vasc Biol 1997; 17: 634-45.
17 Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 1995; 92: 31-8.
18 Courtman DW, Schwartz SM, Hart CE. Sequential injury of the rabbit abdominal aorta induces coagulation and luminal narrowing independent of intimal mass: extrinsic pathway inhibition inhibits luminal narrowing. Circ Res 1998; 82: 996-1006.
19 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. Specificity of a monoclonal antibody for the NH2-terminal region of fibrin. Mol Immunol 1984; 21: 89-94.
20 Bini A, Fenoglio Jr JJ, Mesa-Tejada R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis Use of monoclonal antibodies. Arteriosclerosis 1989; 09: 109-21.
21 Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease The Framingham Study. JAMA 1987; 258: 1183-6.
22 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
23 Meade TW, North WR, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovi’e M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 01: 1050-4.
24 Smith EB, Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res 1994; 73: 1-19.
25 Smith EB. Fibrin deposition and fibrin degradation products in atherosclerotic plaques. Thromb Res 1994; 75: 329-35.
26 Ichikawa K, Nakagawa K, Hirano K, Sueishi K. The localization of tissue factor and apolipoprotein(a) in atherosclerotic lesions of the human aorta and their relation to fibrinogen-fibrin transition. Pathol Res Pract 1996; 192: 224-32.
27 Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226-32.
28 Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest 1996; 75: 451-61.
29 Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394: 200-3.
30 Loike JD, Silverstein R, Wright SD, Weitz JI, Huang AJ, Silverstein SC. The role of protected extracellular compartments in interactions between leukocytes, and platelets, and fibrin/fibrinogen matrices. Ann N Y Acad Sci 1992; 667: 163-72.
31 Nachman RL, Leung LL, Kloczewiak M, Hawiger J. Complex formation of platelet membrane glycoproteins IIb and IIIa with the fibrinogen D domain. J Biol Chem 1984; 259: 8584-8.
32 Marshall JF, Rutherford DC, McCartney AC, Mitjans F, Goodman SL, Hart IR. Alpha v beta 1 is a receptor for vitronectin and fibrinogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin. J Cell Sci 1995; 108: 1227-38.
33 Suehiro K, Gailit J, Plow EF. Fibrinogen is a ligand for integrin alpha5beta1 on endothelial cells. J Biol Chem 1997; 272: 5360-6.
34 Clyman RI, Goetzman BW, Chen YQ, Mauray F, Kramer RH, Pytela R, Schnapp LM. Changes in endothelial cell and smooth muscle cell integrin expression during closure of the ductus arteriosus: an immunohistochemical comparison of the fetal, preterm newborn, and full-term newborn rhesus monkey ductus. Pediatr Res 1996; 40: 198-208.
35 Geary RL, Nikkari ST, Wagner WD, Williams JK, Adams MR, Dean RH. Wound healing: a paradigm for lumen narrowing after arterial reconstruction. J Vasc Surg 1998; 27: 96-106.
36 Mogford JE, Davis GE, Platts SH, Meininger GA. Vascular smooth muscle alpha v beta 3 integrin mediates arteriolar vasodilation in response to RGD peptides. Circ Res 1996; 79: 821-6.